Get the Stockscreener App
2.06
0.98%
0.02
After Hours:
2.02
-0.04
-1.94%
Cadrenal Therapeutics Inc stock is traded at $2.06, with a volume of 70,996.
It is up +0.98% in the last 24 hours and down -32.46% over the past month.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
See More
Previous Close:
$2.04
Open:
$2.14
24h Volume:
70,996
Relative Volume:
0.93
Market Cap:
$6.38M
Revenue:
-
Net Income/Loss:
$-11.89M
P/E Ratio:
-0.3658
EPS:
-5.6317
Net Cash Flow:
$-10.96M
1W Performance:
-1.44%
1M Performance:
-32.46%
6M Performance:
-72.97%
1Y Performance:
-82.07%
1-Day Range:
$1.95
$2.14
1-Week Range:
$1.86
$2.3852
52-Week Range:
$1.86
$14.64
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
2.06 | 6.32M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal Therapeutics Inc (CVKD) Institutional Confidence - TradingKey
Cadrenal Therapeutics Inc (CVKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:2.040|Chg%:+0.010 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Cadrenal Therapeutics Inc (CVKD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cadrenal Therapeutics Market Sentiment - Benzinga España
Cadrenal Therapeutics, Inc. Revenue Breakdown – NASDAQ:CVKD - TradingView
Form PRE 14A CADRENAL THERAPEUTICS For: 23 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) seeks approval for 1M-share equity plan and 960K warrant shares - Stock Titan
H.C. Wainwright Maintains Cadrenal Therapeutics(CVKD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Cadrenal Therapeutics, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy - TipRanks
Cadrenal seeks partners for cardiac care drug portfolio - Investing.com
Cadrenal seeks partners for cardiac care drug portfolio By Investing.com - Investing.com Canada
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation - The Manila Times
Cadrenal's Phase 2 data show >25% absolute reduction in clotting events - Stock Titan
Cadrenal Therapeutics Announces Chief Medical Officer Transition - TipRanks
Cadrenal Therapeutics (NASDAQ: CVKD) outlines CMO Ferguson's exit deal - Stock Titan
Cadrenal Therapeutics (CVKD) Edges Lower Amid Mixed Sentiment, Holding Above Key SupportResistance Breakout Stocks - dars.gov.et
Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing - Stock Titan
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
CADRENAL THERAPEUTICSNO SERIOUS ADVERSE EVENTS OR DEATHS REPORTED WITH CAD-1005 IN PHASE 2 TRIAL - webull.com
Form S-3 Cadrenal Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (NASDAQ: CVKD) files resale for 2.94M warrant shares - Stock Titan
Cadrenal presents phase 2 data for CAD-1005 at ISTH congress - Investing.com Nigeria
Cadrenal presents phase 2 data for CAD-1005 at ISTH congress By Investing.com - Investing.com South Africa
Cadrenal Therapeutics Presents Positive Phase 2 CAD-1005 Data in Late-Breaking ISTH Oral Presentation for Heparin-Induced Thrombocytopenia - Quiver Quantitative
Experimental CAD-1005 drug cuts serious blood clots in HIT patients by over 25% - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Cadrenal Therapeutics Announces Chief Medical Officer Resignation - TipRanks
Cadrenal Therapeutics (CVKD) Chief Medical Officer James Ferguson to step down July 31, 2026 - Stock Titan
Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026 - marketscreener.com
Cadrenal Therapeutics (CVKD) Declines 5.67% as Stock Tests Key Support at $3.00Weak Sell Signals - DonanımHaber
CVKD Q1 2026 Earnings: Narrower-than-expected loss drives positive market reactionEarnings Weakness Phase - dars.gov.et
Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga
Cadrenal Therapeutics Secures Private Placement to Extend Runway - The Globe and Mail
Cadrenal Therapeutics CEO sells $22,422 in stock By Investing.com - Investing.com India
Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes - Stock Titan
Cadrenal Therapeutics CEO sells $22,422 in stock - Investing.com UK
Form 4 Cadrenal Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
(CVKD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants - TradingView
Cadrenal Therapeutics (NASDAQ: CVKD) lines up up to $8.8M via private placement - Stock Titan
Cadrenal Therapeutics Enters Upto $8.8 Mln Private Placement To Extend Cash Runway; Stock Down - RTTNews
Cadrenal raises $3M now, with $5.8M more possible from warrants - Stock Titan
Cadrenal Therapeutics raises $3 million in private placement - Investing.com
Cadrenal Therapeutics raises $3 million in private placement By Investing.com - Investing.com Australia
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):